Cibus (CBUS) Projected to Post Earnings on Tuesday

Cibus (NASDAQ:CBUS) is anticipated to post its Q4 2025 results after the market closes on Tuesday, March 17th. Analysts expect Cibus to post earnings of ($0.43) per share and revenue of $1.6440 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:30 PM ET.

Cibus Stock Down 3.1%

Shares of Cibus stock opened at $3.79 on Monday. The firm has a market cap of $205.72 million, a PE ratio of -1.16 and a beta of 1.62. Cibus has a twelve month low of $1.09 and a twelve month high of $4.19. The business has a 50-day moving average price of $2.56 and a 200 day moving average price of $1.85.

Institutional Investors Weigh In On Cibus

Large investors have recently modified their holdings of the business. Bank of America Corp DE raised its position in shares of Cibus by 113.4% in the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after buying an additional 18,885 shares during the last quarter. AQR Capital Management LLC acquired a new position in Cibus during the first quarter worth about $73,000. Qube Research & Technologies Ltd purchased a new stake in Cibus during the 2nd quarter valued at about $39,000. Raymond James Financial Inc. grew its stake in Cibus by 31.0% during the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after acquiring an additional 12,722 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Cibus in the 2nd quarter valued at about $207,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on CBUS shares. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Cibus in a report on Monday, December 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.00.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.